Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials

References

• Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510–26.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52.
   Google Scholar
• Vega J, Bisognano JD. The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. Semin Nephrol 2014;34:247–56.
   PubMed Web of Science ®Google Scholar
• Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011;57:1076–80.
   PubMed Web of Science ®Google Scholar
• Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 2013;64:233–47.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635–42.
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001;19:2063–70.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20.
   Web of Science ®Google Scholar
• Bakris GL, Townsend RR, Liu M, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Nutr Cardol 2014;64:1071–8.
   PubMed Web of Science ®Google Scholar
• Krum H, Barman N, Schlaich M et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911–7.
   PubMedGoogle Scholar
• Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (London, England) 2010;376:1903–9.
   PubMed Web of Science ®Google Scholar
• Xiong X, Li X, Zhang Y, et al. Chinese herbal medicine for resistant hypertension: a systematic Rev BMJ Open 2015;5:e005355.
   Google Scholar
• Hao PP, Jiang F, Chen YG, et al. Traditional Chinese medication for cardiovascular disease. Nat Rev Cardiol 2015;12:115–22.
   PubMed Web of Science ®Google Scholar
• Makai P, Int Hout J, Grutters JP, et al. Network meta-analysis of various treatment strategies in resistant hypertension. Value Health 2015;18:A377.
   PubMedGoogle Scholar
• Guo H, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. Int J Clin Exp Med 2015;8:7270–8.
   PubMedGoogle Scholar
• Dahal K, Kunwar S, Rijal J, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens 2015;28:1376–85.
   PubMed Web of Science ®Google Scholar
• D’Ascenzo F, Moretti C, Welton N, et al. Medical and interventional therapies for patients with resistant hypertension, a network meta-analysis. EuroIntervention: J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol 2013;9:290.
   Google Scholar
• Václavík J, Sedlák R, Jarkovský J, et al. Effect of spironolactone in resistant arterial hypertension. Medicine 2014;93:e162.
   PubMed Web of Science ®Google Scholar
• Djoumessi RN, Noubiap JJ, Kaze FF, et al. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. BMC Res Notes 2016;9:187.
   PubMedGoogle Scholar
• Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. The Lancet 2015;386:2059–68.
   PubMed Web of Science ®Google Scholar
• Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. The Lancet 2008;371:2219–21.
   PubMed Web of Science ®Google Scholar
• Muxfeldt ES, Barros GS, Viegas BB, et al. Is home blood pressure monitoring useful in the management of patients with resistant hypertension? Am J Hypertens 2015;28:190–9.
   PubMed Web of Science ®Google Scholar
• Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54:475–81.
   PubMed Web of Science ®Google Scholar
• Lane DA, Beevers DG. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J Hypertens 2007;25:2515–6.
   PubMed Web of Science ®Google Scholar
• Verdalles U, Garcia de Vinuesa S, Goicoechea M, et al. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy? Nephrology (Carlton, Vic) 2015;20:567–71.
   Google Scholar
• Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res 2013;50:89–99.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Schiffrin EL. Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circulation Res 2015;116:206–13.
   PubMed Web of Science ®Google Scholar
• Jansen PM, Danser AH, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009;27:680–91.
   PubMed Web of Science ®Google Scholar
• Francis J, Weiss RM, Wei SG, et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circulatory Physiol 2001;281:H2241–51.
   PubMed Web of Science ®Google Scholar
• Kasama S, Toyama T, Kumakura H, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574–81.
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929–33.
   PubMed Web of Science ®Google Scholar
• Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594–7.
   PubMed Web of Science ®Google Scholar
• Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504–10.
   PubMed Web of Science ®Google Scholar
• Vogt S, Winkler E, Hermsen D, et al. Endothelin-1 and adrenomedullin plasma levels after exposure to fludrocortisone, dexamethasone, and spironolactone. Clin Exp Hypertens (New York, NY: 1993) 2012;34:582–7.
   Google Scholar
• London GM. Role of arterial wall properties in the pathogenesis of systolic hypertension. Am J Hypertens 2005;18:19s–22s.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236–41.
   PubMed Web of Science ®Google Scholar
• Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005;18:50–5.
   PubMed Web of Science ®Google Scholar
• Lacolley P, Safar ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:662–7.
   PubMed Web of Science ®Google Scholar
• Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013:2094–102.
   PubMed Web of Science ®Google Scholar
• Abolghasmi R, Taziki O. Efficacy of Low Dose Spironolactone in Chronic Kidney Disease with Resistant Hypertension. Saudi J Kidney Dis Transpl. 2011;22(1):75–8.
   Google Scholar